Evidence map›Paper›PMID 40717483›Full record

ArticleFuture oncology (London, England)2025

A Phase 1 study of the novel GCN2 kinase activator NXP800 in patients with advanced cholangiocarcinoma.

Hendrien Kuipers, Joseph J Larson, Caitlin B Conboy, Daniel H Ahn, Tanios Bekaii-Saab, Christina Wu, Mohamad Bassam Sonbol, Sumera I Ilyas, Gregory J Gores, Rory L Smoot and 1 more

Registry-linked trialAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06420349 (Phase 1b Study of the Novel GCN2 Kinase Activator NXP800 in Patients With Advanced Cholangiocarcionoma), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06420349 phase1terminatednot on this map

Phase 1b Study of the Novel GCN2 Kinase Activator NXP800 in Patients With Advanced Cholangiocarcionoma

TypeinterventionalSponsorMayo ClinicRan2024 to 2025Enrolled7ConditionsAdvanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma, Refractory Cholangiocarcinoma, Stage III Hilar Cholangiocarcinoma AJCC v8ArmsBiospecimen Collection, Computed Tomography, Heat Shock Factor 1 Pathway Inhibitor NXP800, Magnetic Resonance Imaging, Positron Emission Tomography
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Interleukin-6 is critical in the development of pulmonary vascular disease inProceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Hendrien KuipersDepartment of Surgery, Mayo Clinic, Rochester, USA.
Joseph J LarsonDivision of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, USA.
Caitlin B ConboyDivision of Medical Oncology, Mayo Clinic, Rochester, USA.
Daniel H AhnDivision of Hematology and Oncology, Mayo Clinic Cancer Center, Phoenix, USA.
Tanios Bekaii-SaabDivision of Hematology and Oncology, Mayo Clinic Cancer Center, Phoenix, USA.
Christina WuDivision of Hematology and Oncology, Mayo Clinic Cancer Center, Phoenix, USA.
Mohamad Bassam SonbolDivision of Hematology and Oncology, Mayo Clinic Cancer Center, Phoenix, USA.
Sumera I IlyasDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, USA.
Gregory J GoresDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, USA.
Rory L SmootDepartment of Surgery, Mayo Clinic, Rochester, USA.
Mitesh J BoradDivision of Hematology and Oncology, Mayo Clinic Cancer Center, Phoenix, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CLINICAL

trial registrationwww.clinicaltrials.gov identifier is NCT06420349.

Indexed as

Bile Duct NeoplasmsCholangiocarcinomaProtein Serine-Threonine KinasesAgedFemaleHumansMaleMiddle AgedNeoplasm StagingTreatment OutcomeProtein Serine-Threonine KinasesCholangiocarcinomaclinical trialsGCN2integrated stress responseNXP800

Identifiers

PMID40717483
PMCPMC12407588

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.